Tagged with MSD

Indonesia Ashish D. Pal, President Director at MSD Indonesia, discusses the importance of introducing innovative pharmaceuticals, vaccines and biologics to address significant unmet needs and the strategic importance of the universal healthcare coverage program (JKN) towards meeting the national healthcare goals. Mr. Pal, you have been leading the Indonesian affiliate of…

Ireland Much like the Irish sport of hurling, conducting R&D in Ireland is something often overlooked – unfairly, as proponents would say. Ireland has always faced a number of intrinsic hurdles in this space, not least the small patient population and more recently, the economic crisis, which forced the Irish healthcare…

Asia Despite underdevelopment in many facets; Southeast Asia is actually at the forefront of a digital revolution in healthcare; with digital solutions helping bring about more efficient, cost-effective, and tailored patient care. “Cloud-based technology, mobile enablement and fees for service models will lead to faster deployment and increased benefits for patients.…

Ireland Ger Brennan, MD (Human Health) of MSD Ireland, highlights his mandate to position MSD for success in an evolving healthcare landscape, the groundbreaking new report on Irish healthcare attitudes and perspectives MSD commissioned, the opportunities and challenges within the Irish market, and MSD’s commitment to putting patients at the center…

Pharma The CEO of CzechInvest elaborates on the significance of the healthcare and life science industry for the Czech Republic’s transition into an industry 4.0. Furthermore, he reviews what the Czech Republic has to offer for foreign investors over its regional neighbors. Before assuming the position of CEO at CzechInvest you…

Pharma The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare system for Italy, and the vision she has for her company. At the beginning of the New Year, how is…

Pharma The Managing Director of MSD Egypt highlights MSD’s unique incentives to further collaborate with the Egyptian medical community and explains how market peculiarities shape product launches in developing countries like Egypt. As newly appointed Managing Director for MSD Egypt, could you please outline your objectives and ambitions in the Egyptian…

pharma Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic player across the whole of Europe and why 2015 was a significant year for the group, receiving European marketing approval…

MSD The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15 percent growth year on year, why 2014 has been a tough year for the sector and how MSD is focusing…

MSD MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy and incentivizing CRM use to improve operational efficiencies. You took over last year as managing director of MSD Turkey, after…

Merck Andrew Wirths arrived to Puerto Rico in 2013 to run Merck’s manufacturing operations on the island. He discusses how dynamic changes within the industry is impacting their competitive nature and recent investments that Merck is making in Puerto Rico’s facilities, which represent a key part of the company’s commercialization process.…

MSD One of the so-called ‘new generation’ of pharmaceutical GMs in Romania outlines his first impressions of the local market and details how MSD has managed to shape in-county developments in the infectious disease segment and oncology. You have been working in the industry for 26 years and always with MSD.…